Elamipretide (SS-31)
SS-31, SS31, MTP-131, Bendavia, Forzinity, RX-31, Ocuvia
A synthetic mitochondrial tetrapeptide given FDA accelerated approval in 2025 for Barth syndrome only. No trial has tested it against ageing.
Peptides studied in the context of ageing, where almost all evidence is preclinical and human lifespan data does not exist.
Longevity research has a structural problem: the outcome takes a lifetime to measure. Nothing in this area has human lifespan evidence, and claims rest on surrogate markers or on animal models with much shorter lives.
That is not a reason to ignore the research. It is a reason to be precise about what it shows.
SS-31, SS31, MTP-131, Bendavia, Forzinity, RX-31, Ocuvia
A synthetic mitochondrial tetrapeptide given FDA accelerated approval in 2025 for Barth syndrome only. No trial has tested it against ageing.
Epithalon, Epithalone, AEDG, Ala-Glu-Asp-Gly, AEDG peptide
A four-amino-acid peptide studied almost only by one Russian network. No trial with a clinical outcome was found; its lifespan data are from animals.
MOTs-c, MOTs-C, MOTSc, MOTS-C, Mitochondrial-derived peptide MOTS-c, Mitochondrial open reading frame of the 12S rRNA-c
A 16-amino-acid peptide encoded in mitochondrial DNA. Its metabolic and lifespan data come from mice; no human trial of it has reported results.
Evidence review
Elamipretide, epitalon and MOTS-c: no human trial of any of them against ageing was found, and their lifespan data come from mice, rats and flies.